医学
冲程(发动机)
生物标志物
病因学
高强度
内科学
心脏病学
白质
缺血性中风
磁共振成像
缺血
放射科
生物
机械工程
生物化学
工程类
作者
Lukas Holmegaard,Christer Jensen,Annie Pedersén,Christian Blomstrand,Kaj Blennow,Henrik Zetterberg,Katarina Jood,Christina Jern
标识
DOI:10.1038/s41598-024-67232-1
摘要
Abstract Serum neurofilament light chain protein (sNfL) shows promise as a biomarker for infarct size in acute ischemic stroke and for monitoring cerebral small vessel disease (cSVD). However, distinguishing the cSVD contribution after stroke may not be possible due to post-stroke sNfL increase. Additionally, it remains unclear if etiologic subtype differences exist. We measured infarct and white matter hyperintensity (WMH) volumes using MRI at the index stroke in ischemic stroke patients (n = 316, mean age 53 years, 65% males) and at 7-year follow-up (n = 187). Serum NfL concentration was measured in the acute phase (n = 235), at 3-months (n = 288), and 7-years (n = 190) post stroke. In multivariable regression, acute and 3-month sNfL concentrations were associated with infarct volume and time since stroke, but not with stroke etiology or infarct location. Seven years post-stroke, sNfL was associated with WMHs and age, but not with stroke etiology. Nonlinear regression estimated that sNfL peaks around 1 month, and declines by 50% at 3 months, and 99% at 9 months. We conclude that sNfL can indicate infarct volume and time since brain injury in the acute and subacute phases after stroke. Due to the significant post-stroke sNfL increase, several months are needed for reliable assessment of cSVD activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI